Ancillary Prognostic and Predictive Testing in Breast Cancer : Focus on Discordant, Unusual, and Borderline Results - 02/02/18
Abstract |
Ancillary testing in breast cancer has become standard of care to determine what therapies may be most effective for individual patients with breast cancer. Single-marker tests are required on all newly diagnosed and newly metastatic breast cancers. Markers of proliferation are also used, and include both single-marker tests like Ki67 as well as panel-based gene expression tests, which have made more recent contributions to prognostic and predictive testing in breast cancers. This review focuses on pathologist interpretation of these ancillary test results, with a focus on expected versus unexpected results and troubleshooting borderline, unusual, or discordant results.
Le texte complet de cet article est disponible en PDF.Keywords : ER testing, HER2 testing, Fluorescence in situ hybridization (FISH), Molecular testing, Breast cancer, OncotypeDX, Predictive testing
Plan
| Disclosure Statement: No disclosures. |
Vol 11 - N° 1
P. 147-176 - mars 2018 Retour au numéro
Article précédent
- Lobular Carcinoma In Situ
- Hannah Y. Wen, Edi Brogi
- Precursor Lesions of the Low-Grade Breast Neoplasia Pathway
- Laura C. Collins
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?